Wednesday, June 10, 2026

Patent intelligence · EP

EP 3668502

MAKROCYCLISCHE MCL-1-INHIBITOREN UND VERFAHREN ZUR VERWENDUNG

granted A61K 31/ 395 A IA61K/31519A61K/4506A61P 35/ 00 A I
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 14
Applicant portfolio 23
Patent details — EP 3668502
Jurisdiction
EP
Status
granted
Grant date
Jun 24, 2020
Expiration
Jun 19, 2040
Applicant
ABBVIE INC [US]
CPC classes
A61K 31/ 395 A I, A61K/31519, A61K/4506, A61P 35/ 00 A I
View on Google Patents ↗

Quick answer

EP 3668502 (MAKROCYCLISCHE MCL-1-INHIBITOREN UND VERFAHREN ZUR VERWENDUNG) is held by ABBVIE INC [US]. Status: granted. Granted Jun 24, 2020. Expires Jun 19, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
ABBVIE INC [US]
Grant date
Expiration
Claims
CPC classes
A61K 31/ 395 A I, A61K/31519, A61K/4506, A61P 35/ 00 A I, A61P/3500

More from ABBVIE INC [US]

Related pharmaceutical patents in our USPTO index.

  1. WO 2024243450

    MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET

    ABBVIE INC [US] · Expires Nov 23, 2044

    granted
  2. CA 3266054

    COMPOSÉS DE N-MÉTHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE

    ABBVIE DEUTSCHLAND [DE] · Expires Mar 2, 2044

    granted
  3. CA 3259391

    POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1

    ABBVIE BIOTHERAPEUTICS INC [US] · Expires Jan 27, 2044

    granted
  4. CA 3245150

    COMBINAISONS AVEC UN ANTICORPS ANTI-CD39 HUMAIN, UN ANTICORPS ANTI-PD-1 HUMAIN ET UNE CHIMIOTHÉRAPIE CONTRE LE CANCER GASTRIQUE

    TRISHULA THERAPEUTICS INC [US] · Expires Sep 2, 2043

    granted
  5. US 2023174645

    ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS

    DISC MEDICINE INC [US] · Expires Jun 3, 2043

    granted
  6. CA 3235096

    METHODES DE TRAITEMENT DE L'ANEMIE CAUSEE PAR UNE MALADIE RENALE

    DISC MEDICINE INC [US] · Expires May 20, 2043

    granted
  7. CA 3207179

    METHODES DE TRAITEMENT DE LA MALADIE DE CROHN ET DE LA COLITE ULCEREUSE

    ABBVIE INC [US] · Expires Jul 9, 2042

    granted
  8. US 2022169620

    SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS

    ABBVIE DEUTSCHLAND [DE] · Expires May 28, 2042

    granted

Frequently asked questions

What is US patent 3668502?

EP 3668502 (MAKROCYCLISCHE MCL-1-INHIBITOREN UND VERFAHREN ZUR VERWENDUNG) is held by ABBVIE INC [US]. Status: granted. Granted Jun 24, 2020. Expires Jun 19, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns EP 3668502?

ABBVIE INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 23 pharmaceutical patents for this assignee.

When does EP 3668502 expire?

Our index shows an expiration date of Jun 19, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.